share_log

維亞生物：截至二零二三年十二月三十一日止月份股份發行人的證券變動月報表

VIVA BIOTECH: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2023

香港交易所 ·  Jan 5 02:28
Summary by Moomoo AI
维亚生物科技控股集团於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本及已發行股份在該月份未有變動，維持在4,000,000,000股，每股面值0.000025美元，總額100,000美元。此外，公司的股份期權計劃包括首次公開發售前股份獎勵計劃和首次公開發售後購股權計劃，均未有新的股份期權行使或失效。報告還提到，2025年到期的有擔保可換股債券已於本月內全數贖回，並無新的股份因此發行。公司確認所有證券發行均獲董事會批准，並符合相關法律規定。
维亚生物科技控股集团於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本及已發行股份在該月份未有變動，維持在4,000,000,000股，每股面值0.000025美元，總額100,000美元。此外，公司的股份期權計劃包括首次公開發售前股份獎勵計劃和首次公開發售後購股權計劃，均未有新的股份期權行使或失效。報告還提到，2025年到期的有擔保可換股債券已於本月內全數贖回，並無新的股份因此發行。公司確認所有證券發行均獲董事會批准，並符合相關法律規定。
VIA Biotechnology Holding Group filed with Hong Kong Trading and Settlement Limited on 5 January 2024 the Monthly Securities Change Report for the year ended 31 December 2023. The report showed that the company's regulated/registered share capital and issued shares remained unchanged for the month at 4,000,000,000 shares with a face value of $0.000025 per share for a total of $100,000. In addition, the Company's stock option plans, including the Initial Public Offering Share Reward Program and the Initial Public Post-Public Offering Option Plan, are free from the exercise or expiration of new stock options. The report also noted that the Guaranteed Convertible Notes due 2025 were redeemed in full this month and no new shares were issued as a result. The Company confirms that all securities issuances are approved by the Board of Directors and comply with relevant legal requirements.
VIA Biotechnology Holding Group filed with Hong Kong Trading and Settlement Limited on 5 January 2024 the Monthly Securities Change Report for the year ended 31 December 2023. The report showed that the company's regulated/registered share capital and issued shares remained unchanged for the month at 4,000,000,000 shares with a face value of $0.000025 per share for a total of $100,000. In addition, the Company's stock option plans, including the Initial Public Offering Share Reward Program and the Initial Public Post-Public Offering Option Plan, are free from the exercise or expiration of new stock options. The report also noted that the Guaranteed Convertible Notes due 2025 were redeemed in full this month and no new shares were issued as a result. The Company confirms that all securities issuances are approved by the Board of Directors and comply with relevant legal requirements.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more